Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s budget in limbo

This article was originally published in The Rose Sheet

Executive Summary

The 109th Congress failed to pass appropriations for FDA for FY 2007, instead settling on a continuing resolution that expires Feb. 15. Incoming Democratic Appropriations Committee Chairmen Sen. Robert Byrd (W.Va.) and Rep. Dave Obey (Wisc.) plan to scrap the current Republican appropriations bills in favor of a year-long continuing resolution. The move would effectively freeze the agency's spending at FY 2006 levels until FY 2008 begins. FDA responded by stating that "a full-year continuing resolution presents difficult challenges." The agency added that between now and Feb. 15, it "will be working with the administration to analyze the impacts of a continuing resolution"...

You may also be interested in...



CFSAN Restricts Cosmetics Inspections To Limited Basis If Budget Refused

FDA will eliminate routine cosmetics inspections in fiscal year 2008 and only perform them on a "for cause" basis if the agency is forced to operate at 2006 levels under a continuing resolution, according to FDA's Feb. 5 request

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel